Kaivola Karri, Pirinen Matti, Laaksovirta Hannu, Jansson Lilja, Rautila Osma, Launes Jyrki, Hokkanen Laura, Lahti Jari, Eriksson Johan G, Strandberg Timo E, Tienari Pentti J
Translational Immunology, Research Programs Unit, University of Helsinki, Helsinki, Finland.
Department of Neurology, Helsinki University Hospital, Helsinki, Finland.
Front Genet. 2023 Mar 1;14:1087098. doi: 10.3389/fgene.2023.1087098. eCollection 2023.
hexanucleotide repeat expansion is a common cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The locus may harbor residual risk outside the hexanucleotide repeat expansion, but the evidence is conflicting. Here, we first compared 683 unrelated amyotrophic lateral sclerosis cases and 3,196 controls with Finnish ancestry to find best single nucleotide polymorphisms that tag the hexanucleotide repeat expansion and intermediate-length alleles. Rs2814707 was the best tagging single nucleotide polymorphisms for intermediate-length alleles with ≥7 repeats ( = 5 × 10) and rs139185008 for the hexanucleotide repeat expansion ( = 7 × 10) as well as alleles with ≥20 repeats. rs139185008C associated with amyotrophic lateral sclerosis after removing cases with the hexanucleotide repeat expansion, especially in the subpopulation homozygous for the rs2814707T ( = 0.0002, OR = 5.06), which supports the concept of residual amyotrophic lateral sclerosis risk at the haplotypes other than the hexanucleotide repeat expansion. We then leveraged Finnish biobank data to test the effects of rs2814707T and rs139185008C on longevity after removing individuals with amyotrophic lateral sclerosis / frontotemporal dementia diagnoses. In the discovery cohort ( = 230,006), the frequency of rs139185008C heterozygotes decreased significantly with age in the comparisons between 50 and 80 years vs. >80 years ( = 0.0005) and <50 years vs. >80 years ( = 0.0001). The findings were similar but less significant in a smaller replication cohort (2-sided = 0.037 in 50-80 years vs. >80 years and 0.061 in <50 years vs. >80 years). Analysis of the allele frequencies in 5-year bins demonstrated that the decrease of rs139185008C started after the age of 70 years. The hexanucleotide repeat expansion tagging single nucleotide polymorphisms decreasing frequency with age suggests its' association with age-related diseases probably also outside amyotrophic lateral sclerosis / frontotemporal dementia.
六核苷酸重复序列扩增是肌萎缩侧索硬化症(ALS)和额颞叶痴呆(FTD)的常见病因。该位点可能在六核苷酸重复序列扩增之外还存在残余风险,但证据存在矛盾。在此,我们首先比较了683例无亲缘关系的芬兰裔肌萎缩侧索硬化症患者和3196名对照,以寻找能标记六核苷酸重复序列扩增和中等长度等位基因的最佳单核苷酸多态性。Rs2814707是中等长度等位基因(≥7次重复,P = 5×10)的最佳标记单核苷酸多态性,而rs139185008是六核苷酸重复序列扩增(P = 7×10)以及≥20次重复等位基因的最佳标记单核苷酸多态性。在去除六核苷酸重复序列扩增的病例后,rs139185008C与肌萎缩侧索硬化症相关,尤其在rs2814707T纯合子亚组中(P = 0.0002,OR = 5.06),这支持了在六核苷酸重复序列扩增以外的单倍型存在残余肌萎缩侧索硬化症风险的概念。然后,我们利用芬兰生物样本库数据,在去除肌萎缩侧索硬化症/额颞叶痴呆诊断个体后,测试rs2814707T和rs139185008C对寿命的影响。在发现队列(n = 230,006)中,在50至80岁与>80岁(P = 0.0005)以及<50岁与>80岁(P = 0.0001)的比较中,rs139185008C杂合子的频率随年龄显著降低。在较小的重复队列中结果相似但显著性较低(50 - 80岁与>80岁比较时双侧P = 0.037,<50岁与>80岁比较时P = 0.061)。以5年为间隔分析等位基因频率表明,rs139185008C频率的降低始于70岁以后。六核苷酸重复序列扩增标记单核苷酸多态性随年龄降低频率表明其可能也与肌萎缩侧索硬化症/额颞叶痴呆以外的年龄相关疾病有关。